FDA Probes Serious Risk Of Secondary Cancer Following CAR T Cell Therapies

The Food and Drug Administration or FDA said it is investigating serious risk of T-cell malignancies following BCMA or CD19-directed autologous Chimeric Antigen Receptor or CAR T cell Immunotherapies. However, the overall benefits of these products continue to outweigh their potential risks for their approved uses.

from RTT - Top Story https://ift.tt/GvlLQNq
via IFTTT